ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

NIH Seeking More Women, Minorities On Committees

November 9, 1979

RFAs available: Chemoprevention Clinical Trials

July 22, 1994

In Brief: ASCO Congratulates Klausner; UCLA Names Gasson Head Of Jonsson Center

August 4, 1995

CAP, ASCCP Recommendations Standardize Lesion Terminology

July 27, 2012

Young Molecular Biologists Optimistic, Survey Finds

February 21, 1997

DCE Advisors Approve New Epidemiology RFPs Table Proposed RFA

April 16, 1993